UPDATE: Piper Jaffray Lifts Synageva PT on Attractive Upcoming LAL-D Treatment
Piper Jaffray published a report Monday that maintained a Neutral rating on Synageva (NASDAQ: GEVA) and raised its price target from $53 to $57.
Piper Jaffray noted, "We continue to believe sebelipase alfa represents an attractive treatment option for LAL-D, with recent 38 week Phase I/II data providing additional confirmation of the drug's long-term clinical utility. Despite our enthusiasm for sebelipase alfa, we remain Neutral on GEVA shares given what we see to be an absence of meaningful newsflow following the commencement of the ARISE Phase III trial in January. While we remain positive on GEVA shares over the longer term, we believe shares will remain range-bound as the trial progresses."
Synageva closed Monday at $54.28.
Latest Ratings for GEVA
|Mar 2015||JP Morgan||Downgrades||Overweight||Neutral|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.